Literature DB >> 23899291

Exquisite selectivity for human toll-like receptor 8 in substituted furo[2,3-c]quinolines.

Hari Prasad Kokatla1, Diptesh Sil, Subbalakshmi S Malladi, Rajalakshmi Balakrishna, Alec R Hermanson, Lauren M Fox, Xinkun Wang, Anshuman Dixit, Sunil A David.   

Abstract

Toll-like receptor (TLR)-8 agonists activate adaptive immune responses by inducing robust production of T helper 1-polarizing cytokines, suggesting that TLR8-active compounds may be promising candidate adjuvants. We synthesized and evaluated hitherto unexplored furo[2,3-c]quinolines and regioisomeric furo[3,2-c]quinolines derived via a tandem, one-pot Sonogashira coupling and intramolecular 5-endo-dig cyclization strategy in a panel of primary screens. We observed a pure TLR8-agonistic activity profile in select furo[2,3-c]quinolines, with maximal potency conferred by a C2-butyl group (EC50 = 1.6 μM); shorter, longer, or substituted homologues as well as compounds bearing C1 substitutions were inactive, which was rationalized by docking studies using the recently described crystal structure of human TLR8. The best-in-class compound displayed prominent proinflammatory cytokine induction (including interleukin-12 and interleukin-18), but was bereft of interferon-α inducing properties, confirming its high selectivity for human TLR8.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23899291      PMCID: PMC3790333          DOI: 10.1021/jm400694d

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  59 in total

1.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening.

Authors:  Thomas A Halgren; Robert B Murphy; Richard A Friesner; Hege S Beard; Leah L Frye; W Thomas Pollard; Jay L Banks
Journal:  J Med Chem       Date:  2004-03-25       Impact factor: 7.446

2.  TLR8-mediated NF-kappaB and JNK activation are TAK1-independent and MEKK3-dependent.

Authors:  Jinzhong Qin; Jianhong Yao; Grace Cui; Hui Xiao; Tae Whan Kim; Jerzy Fraczek; Paul Wightman; Shintaro Sato; Shizuo Akira; Anne Puel; Jean-Laurent Casanova; Bing Su; Xiaoxia Li
Journal:  J Biol Chem       Date:  2006-05-31       Impact factor: 5.157

Review 3.  Regulatory T cells--a journey from rodents to the clinic.

Authors:  Elaine T Long; Kathryn J Wood
Journal:  Front Biosci       Date:  2007-05-01

4.  Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8.

Authors:  Keith B Gorden; Kevin S Gorski; Sheila J Gibson; Ross M Kedl; William C Kieper; Xiaohong Qiu; Mark A Tomai; Sefik S Alkan; John P Vasilakos
Journal:  J Immunol       Date:  2005-02-01       Impact factor: 5.422

5.  Lipopolysaccharide sequestrants: structural correlates of activity and toxicity in novel acylhomospermines.

Authors:  Kelly A Miller; E V K Suresh Kumar; Stewart J Wood; Jens R Cromer; Apurba Datta; Sunil A David
Journal:  J Med Chem       Date:  2005-04-07       Impact factor: 7.446

6.  TLR2 engagement on CD8 T cells lowers the threshold for optimal antigen-induced T cell activation.

Authors:  Anne Cottalorda; Claire Verschelde; Antoine Marçais; Martine Tomkowiak; Philippe Musette; Satoshi Uematsu; Shizuo Akira; Jacqueline Marvel; Nathalie Bonnefoy-Berard
Journal:  Eur J Immunol       Date:  2006-07       Impact factor: 5.532

7.  Toll-like receptor (TLR)-7 and -8 modulatory activities of dimeric imidazoquinolines.

Authors:  Nikunj M Shukla; Cole A Mutz; Subbalakshmi S Malladi; Hemamali J Warshakoon; Rajalakshmi Balakrishna; Sunil A David
Journal:  J Med Chem       Date:  2012-01-27       Impact factor: 7.446

8.  Comparison of the immunostimulatory and proinflammatory activities of candidate Gram-positive endotoxins, lipoteichoic acid, peptidoglycan, and lipopeptides, in murine and human cells.

Authors:  Matthew R Kimbrell; Hemamali Warshakoon; Jens R Cromer; Subbalakshmi Malladi; Jennifer D Hood; Rajalakshmi Balakrishna; Tandace A Scholdberg; Sunil A David
Journal:  Immunol Lett       Date:  2008-04-18       Impact factor: 3.685

Review 9.  Regulatory T cells, transforming growth factor-beta, and immune suppression.

Authors:  Yisong Y Wan; Richard A Flavell
Journal:  Proc Am Thorac Soc       Date:  2007-07

10.  Potent adjuvanticity of a pure TLR7-agonistic imidazoquinoline dendrimer.

Authors:  Nikunj M Shukla; Deepak B Salunke; Rajalakshmi Balakrishna; Cole A Mutz; Subbalakshmi S Malladi; Sunil A David
Journal:  PLoS One       Date:  2012-08-28       Impact factor: 3.240

View more
  15 in total

Review 1.  Strategies for designing synthetic immune agonists.

Authors:  Tom Y-H Wu
Journal:  Immunology       Date:  2016-07-11       Impact factor: 7.397

2.  Design and Synthesis of N1-Modified Imidazoquinoline Agonists for Selective Activation of Toll-like Receptors 7 and 8.

Authors:  Peter Larson; Tamara A Kucaba; Zhengming Xiong; Michael Olin; Thomas S Griffith; David M Ferguson
Journal:  ACS Med Chem Lett       Date:  2017-10-16       Impact factor: 4.345

3.  Structure-based design of novel human Toll-like receptor 8 agonists.

Authors:  Hari Prasad Kokatla; Diptesh Sil; Hiromi Tanji; Umeharu Ohto; Subbalakshmi S Malladi; Lauren M Fox; Toshiyoki Shimizu; Sunil A David
Journal:  ChemMedChem       Date:  2014-01-28       Impact factor: 3.466

Review 4.  Directing the immune system with chemical compounds.

Authors:  Rock J Mancini; Lalisa Stutts; Keun Ah Ryu; Janine K Tom; Aaron P Esser-Kahn
Journal:  ACS Chem Biol       Date:  2014-04-30       Impact factor: 5.100

5.  The Imidazoquinoline Toll-Like Receptor-7/8 Agonist Hybrid-2 Potently Induces Cytokine Production by Human Newborn and Adult Leukocytes.

Authors:  Lakshmi Ganapathi; Simon Van Haren; David J Dowling; Ilana Bergelson; Nikunj M Shukla; Subbalakshmi S Malladi; Rajalakshmi Balakrishna; Hiromi Tanji; Umeharu Ohto; Toshiyuki Shimizu; Sunil A David; Ofer Levy
Journal:  PLoS One       Date:  2015-08-14       Impact factor: 3.240

6.  Identification of Adjuvantic Activity of Amphotericin B in a Novel, Multiplexed, Poly-TLR/NLR High-Throughput Screen.

Authors:  Alex C D Salyer; Giuseppe Caruso; Karishma K Khetani; Lauren M Fox; Subbalakshmi S Malladi; Sunil A David
Journal:  PLoS One       Date:  2016-02-26       Impact factor: 3.240

7.  Structure-Based Design of Human TLR8-Specific Agonists with Augmented Potency and Adjuvanticity.

Authors:  Mallesh Beesu; Giuseppe Caruso; Alex C D Salyer; Karishma K Khetani; Diptesh Sil; Mihiri Weerasinghe; Hiromi Tanji; Umeharu Ohto; Toshiyuki Shimizu; Sunil A David
Journal:  J Med Chem       Date:  2015-09-22       Impact factor: 7.446

Review 8.  Structural evolution of toll-like receptor 7/8 agonists from imidazoquinolines to imidazoles.

Authors:  Deepender Kaushik; Arshpreet Kaur; Nikolai Petrovsky; Deepak B Salunke
Journal:  RSC Med Chem       Date:  2021-05-14

9.  Determinants of activity at human Toll-like receptors 7 and 8: quantitative structure-activity relationship (QSAR) of diverse heterocyclic scaffolds.

Authors:  Euna Yoo; Deepak B Salunke; Diptesh Sil; Xiaoqiang Guo; Alex C D Salyer; Alec R Hermanson; Manoj Kumar; Subbalakshmi S Malladi; Rajalakshmi Balakrishna; Ward H Thompson; Hiromi Tanji; Umeharu Ohto; Toshiyuki Shimizu; Sunil A David
Journal:  J Med Chem       Date:  2014-09-17       Impact factor: 7.446

10.  Human Toll-like receptor 8-selective agonistic activities in 1-alkyl-1H-benzimidazol-2-amines.

Authors:  Mallesh Beesu; Subbalakshmi S Malladi; Lauren M Fox; Cassandra D Jones; Anshuman Dixit; Sunil A David
Journal:  J Med Chem       Date:  2014-08-20       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.